TxCell’s novel CAR-modified regulatory T-cell (CAR Treg) platform is developing well. CAR Tregs offer a powerful and versatile new approach to autoimmune and immune system disorders. TxCell has four indications in preclinical development with the first ever CAR Treg trial, in transplant rejection, anticipated by TxCell to start by late 2018. This could provide powerful clinical proof-of-concept data by 2020. Ovasave for Crohn’s disease remains as a clinical-stage project but is cu
28 Feb 2017
Exciting CAR opportunities; multiple indications
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Exciting CAR opportunities; multiple indications
Txcell (TXCL:EPA) | 0 0 -1.3% | Mkt Cap: 29.4m
- Published:
28 Feb 2017 -
Author:
Dr John Savin -
Pages:
16
TxCell’s novel CAR-modified regulatory T-cell (CAR Treg) platform is developing well. CAR Tregs offer a powerful and versatile new approach to autoimmune and immune system disorders. TxCell has four indications in preclinical development with the first ever CAR Treg trial, in transplant rejection, anticipated by TxCell to start by late 2018. This could provide powerful clinical proof-of-concept data by 2020. Ovasave for Crohn’s disease remains as a clinical-stage project but is cu